{"id":"https://openalex.org/W2954643241","doi":"https://doi.org/10.1158/1538-7445.am2019-4025","title":"Abstract 4025: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers","display_name":"Abstract 4025: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers","publication_year":2019,"publication_date":"2019-07-01","ids":{"openalex":"https://openalex.org/W2954643241","doi":"https://doi.org/10.1158/1538-7445.am2019-4025","mag":"2954643241"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2019-4025","doi":"https://doi.org/10.1158/1538-7445.am2019-4025","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-4025","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5013014678","display_name":"Hui Yu","orcid":"https://orcid.org/0000-0002-1525-632X","observed_orcids":["https://orcid.org/0000-0002-1525-632X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hui Yu","raw_affiliation_strings":["1University of Colorado, Aurora, CO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of Colorado, Aurora, CO;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051692752","display_name":"Shevan Silva","orcid":"https://orcid.org/0000-0002-9942-1897","observed_orcids":["https://orcid.org/0000-0002-9942-1897"]},"institutions":[{"id":"https://openalex.org/I154130895","display_name":"University of Auckland","ror":"https://ror.org/03b94tp07","country_code":"NZ","type":"education","lineage":["https://openalex.org/I154130895"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"Shevan Silva","raw_affiliation_strings":["2The University of Auckland, Auckland, New Zealand;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2The University of Auckland, Auckland, New Zealand;","institution_ids":["https://openalex.org/I154130895"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022348436","display_name":"Adriana Estrada\u2010Bernal","orcid":"https://orcid.org/0000-0002-0555-2766","observed_orcids":["https://orcid.org/0000-0002-0555-2766"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Adriana Estrada-Bernal","raw_affiliation_strings":["3Rain Therapeutics Inc., Fremont, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Rain Therapeutics Inc., Fremont, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036727605","display_name":"Chris J. Rivard","orcid":"https://orcid.org/0000-0002-6328-5600","observed_orcids":["https://orcid.org/0000-0002-6328-5600"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chris Rivard","raw_affiliation_strings":["1University of Colorado, Aurora, CO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of Colorado, Aurora, CO;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103158981","display_name":"Fred R. Hirsch","orcid":"https://orcid.org/0000-0002-9213-4414","observed_orcids":["https://orcid.org/0000-0002-9213-4414"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fred Hirsch","raw_affiliation_strings":["1University of Colorado, Aurora, CO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of Colorado, Aurora, CO;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002860629","display_name":"Maria Abbatista","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I154130895","display_name":"University of Auckland","ror":"https://ror.org/03b94tp07","country_code":"NZ","type":"education","lineage":["https://openalex.org/I154130895"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"Maria Abbatista","raw_affiliation_strings":["2The University of Auckland, Auckland, New Zealand;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2The University of Auckland, Auckland, New Zealand;","institution_ids":["https://openalex.org/I154130895"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030727604","display_name":"Jeff Bruce Smaill","orcid":"https://orcid.org/0000-0003-2954-6093","observed_orcids":["https://orcid.org/0000-0003-2954-6093"]},"institutions":[{"id":"https://openalex.org/I154130895","display_name":"University of Auckland","ror":"https://ror.org/03b94tp07","country_code":"NZ","type":"education","lineage":["https://openalex.org/I154130895"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"Jeff Smaill","raw_affiliation_strings":["2The University of Auckland, Auckland, New Zealand;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2The University of Auckland, Auckland, New Zealand;","institution_ids":["https://openalex.org/I154130895"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034705456","display_name":"Robert Charles Doebele","orcid":"https://orcid.org/0000-0001-6728-6857","observed_orcids":["https://orcid.org/0000-0001-6728-6857"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert C. Doebele","raw_affiliation_strings":["3Rain Therapeutics Inc., Fremont, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Rain Therapeutics Inc., Fremont, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024840477","display_name":"Adam Vorn Patterson","orcid":"https://orcid.org/0000-0001-5138-1227","observed_orcids":["https://orcid.org/0000-0001-5138-1227"]},"institutions":[{"id":"https://openalex.org/I154130895","display_name":"University of Auckland","ror":"https://ror.org/03b94tp07","country_code":"NZ","type":"education","lineage":["https://openalex.org/I154130895"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"Adam Patterson","raw_affiliation_strings":["2The University of Auckland, Auckland, New Zealand;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2The University of Auckland, Auckland, New Zealand;","institution_ids":["https://openalex.org/I154130895"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025050482","display_name":"Avanish Vellanki","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Avanish Vellanki","raw_affiliation_strings":["3Rain Therapeutics Inc., Fremont, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Rain Therapeutics Inc., Fremont, CA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5037183800","display_name":"Vijaya G. Tirunagaru","orcid":"https://orcid.org/0000-0002-6505-8858","observed_orcids":["https://orcid.org/0000-0002-6505-8858"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vijaya G. Tirunagaru","raw_affiliation_strings":["3Rain Therapeutics Inc., Fremont, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Rain Therapeutics Inc., Fremont, CA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"79","issue":"13_Supplement","first_page":"4025","last_page":"4025"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.8955000042915344,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.8955000042915344,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0820000022649765,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12356","display_name":"Bioactive Compounds and Antitumor Agents","score":0.002400000113993883,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/steap4","display_name":"STEAP4","score":0.9739999771118164},{"id":"https://openalex.org/keywords/prodrug-activation","display_name":"prodrug activation","score":0.7329999804496765},{"id":"https://openalex.org/keywords/egfr-mutation","display_name":"EGFR mutation","score":0.7599999904632568},{"id":"https://openalex.org/keywords/her2-mutation","display_name":"HER2 mutation","score":0.9980000257492065},{"id":"https://openalex.org/keywords/one-electron-reduction","display_name":"one-electron reduction","score":0.8399999737739563},{"id":"https://openalex.org/keywords/tumor-hypoxia","display_name":"tumor hypoxia","score":0.9399999976158142},{"id":"https://openalex.org/keywords/in-situ-hybridization","display_name":"in situ hybridization","score":0.6959999799728394},{"id":"https://openalex.org/keywords/immunohistochemistry","display_name":"immunohistochemistry","score":0.9829999804496765},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.7749999761581421},{"id":"https://openalex.org/keywords/patient-stratification","display_name":"patient stratification","score":0.871999979019165},{"id":"https://openalex.org/keywords/tumor-xenografts","display_name":"tumor xenografts","score":0.6159999966621399},{"id":"https://openalex.org/keywords/patient-derived-tumor-tissue","display_name":"patient-derived tumor tissue","score":0.4129999876022339}],"concepts":[{"id":"https://openalex.org/C204232928","wikidata":"https://www.wikidata.org/wiki/Q899285","display_name":"Immunohistochemistry","level":2,"score":0.777698814868927},{"id":"https://openalex.org/C81439078","wikidata":"https://www.wikidata.org/wiki/Q2304142","display_name":"In situ hybridization","level":4,"score":0.4548121988773346},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4203881323337555},{"id":"https://openalex.org/C105580179","wikidata":"https://www.wikidata.org/wiki/Q188928","display_name":"Messenger RNA","level":3,"score":0.38822656869888306},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.37645813822746277},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.3298768401145935},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.32638171315193176},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2354145050048828},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2048833966255188},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.16516873240470886},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1149480938911438}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2019-4025","doi":"https://doi.org/10.1158/1538-7445.am2019-4025","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-4025","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.6299999952316284}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3115703756","https://openalex.org/W2890353668","https://openalex.org/W4387812350","https://openalex.org/W2291585432","https://openalex.org/W3185304886","https://openalex.org/W2982083339","https://openalex.org/W3135184108","https://openalex.org/W2786975350","https://openalex.org/W2955541041","https://openalex.org/W4250465857"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Tarloxotinib":[2,253,272,300,347],"is":[3,293],"a":[4,9,87,112],"clinical-stage":[5],"prodrug":[6],"that":[7,56],"releases":[8],"potent,":[10],"irreversible":[11],"EGFR/HER2":[12,180,185,241,261,350],"inhibitor":[13],"(Tarloxotinib-E)":[14],"selectively":[15],"in":[16,72,95,121,175,227,240,260,283,290,299,312,349],"severely":[17],"hypoxic":[18,284],"regions":[19],"of":[20,27,42,60,119,178,222,238,287,356],"tumors.":[21,230,244,285],"One-electron":[22],"reduction":[23,59],"leads":[24,274],"to":[25,85,89,157,213,255,275,278,295,308],"loss":[26],"the":[28,35,43,51,276,279,357],"trigger":[29],"moiety":[30],"under":[31],"oxygen-deficient":[32],"conditions,":[33],"releasing":[34],"neutral,":[36],"diffusible":[37],"\u2018warhead\u2019":[38],"Tarloxotinib-E.":[39,256],"CRISPR/cas9-mediated":[40],"disruption":[41],"metalloreductase":[44],"STEAP4":[45,91,108,120,124,132,144,170,192,207,223,228,231,245,257,270,288,341],"has":[46],"demonstrated":[47],"its":[48],"role":[49],"as":[50,136],"dominant":[52],"plasma":[53],"membrane":[54],"reductase":[55],"facilitates":[57],"one-electron":[58],"Tarloxotinib.":[61],"Methods:":[62],"Cancer":[63,361,375],"cell":[64,148,204],"lines,":[65],"PDX":[66],"and":[67,146,150,164,184,198,206,211,247,273,303,343],"resected":[68],"tumor":[69,151,182,188,209,264],"tissues":[70],"processed":[71],"Formalin":[73],"Fixed":[74],"Paraffin":[75],"Embedded":[76],"(FFPE)":[77],"blocks":[78,210],"were":[79,126],"evaluated.":[80],"RNAScope":[81],"technology":[82,106],"was":[83,109,134,155,173,196,225],"used":[84],"develop":[86],"method":[88],"assess":[90],"mRNA":[92,104,162,171,193,224,232,246,258],"expression":[93,172,239,249,259,289],"by":[94],"situ":[96],"hybridization":[97],"using":[98,138,200],"specific":[99],"probes":[100],"for":[101,107,117,128,161,168,346,360],"human":[102],"STEAP4.":[103],"ISH":[105,163,194,233,342],"optimized":[110,197],"on":[111],"Leica":[113],"Bond":[114],"RX":[115],"autostainer":[116],"detection":[118],"FFPE":[122,176,201],"specimens.":[123,189],"antibodies":[125],"evaluated":[127],"Immunohistochemistry":[129],"(IHC)":[130],"analysis.":[131],"IHC":[133,344],"employed":[135],"cross-reference,":[137],"an":[139,305],"anti-STEAP4":[140],"antibody":[141],"validated":[142,199],"against":[143],"knockout":[145],"over-expressing":[147],"line":[149],"models.":[152],"Staining":[153],"data":[154],"compared":[156,212],"quantitative":[158],"PCR":[159],"results":[160],"Western":[165],"blot":[166],"analysis":[167,234],"IHC.":[169],"assessed":[174],"sections":[177,202],"various":[179],"mutant":[181,186,242,262,351],"xenografts":[183],"patient":[187,263,297],"Results:":[190],"The":[191],"assay":[195],"from":[203],"lines":[205],"overexpressing":[208,229],"wild":[214],"type":[215],"tumors":[216],"with":[217,252],"minimal":[218],"expression.":[219],"High":[220],"level":[221,250],"observed":[226],"revealed":[235],"variable":[236],"levels":[237],"xenograft":[243],"protein":[248],"correlated":[251],"conversion":[254,277],"specimens":[265],"will":[266],"be":[267],"presented.":[268],"Conclusion:":[269],"reduces":[271],"active":[280],"drug,":[281],"Tarloxotinib-E,":[282],"Assessment":[286],"individual":[291],"patients":[292,311],"important":[294],"guide":[296],"stratification":[298],"clinical":[301,313],"trials":[302],"represents":[304],"attractive":[306],"biomarker":[307],"enroll":[309],"tarloxotinib-responsive":[310],"trials.":[314],"Citation":[315],"Format:":[316],"Hui":[317],"Yu,":[318],"Shevan":[319],"Silva,":[320],"Adriana":[321],"Estrada-Bernal,":[322],"Chris":[323],"Rivard,":[324],"Fred":[325],"Hirsch,":[326],"Maria":[327],"Abbatista,":[328],"Jeff":[329],"Smaill,":[330],"Robert":[331],"C.":[332],"Doebele,":[333],"Adam":[334],"Patterson,":[335],"Avanish":[336],"Vellanki,":[337],"Vijaya":[338],"G.":[339],"Tirunagaru.":[340],"diagnostics":[345],"activation":[348],"cancers":[352],"[abstract].":[353],"In:":[354],"Proceedings":[355],"American":[358],"Association":[359],"Research":[362],"Annual":[363],"Meeting":[364],"2019;":[365],"2019":[366],"Mar":[367],"29-Apr":[368],"3;":[369],"Atlanta,":[370],"GA.":[371],"Philadelphia":[372],"(PA):":[373],"AACR;":[374],"Res":[376],"2019;79(13":[377],"Suppl):Abstract":[378],"nr":[379],"4025.":[380]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":3}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2019-07-12T00:00:00"}